- Home
- VRCA vs ZYXI Comparison
VRCA vs ZYXI Comparison
Compare VRCA & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- ZYXI
- Stock Information
- Founded
- VRCA 2013
- ZYXI 1996
- Country
- VRCA United States
- ZYXI United States
- Employees
- VRCA N/A
- ZYXI N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VRCA Health Care
- ZYXI Health Care
- Exchange
- VRCA Nasdaq
- ZYXI Nasdaq
- Market Cap
- VRCA 80.7M
- ZYXI 72.3M
- IPO Year
- VRCA 2018
- ZYXI N/A
- Fundamental
- Price
- VRCA $5.99
- ZYXI $2.49
- Analyst Decision
- VRCA Hold
- ZYXI Buy
- Analyst Count
- VRCA 5
- ZYXI 3
- Target Price
- VRCA $6.00
- ZYXI $5.50
- AVG Volume (30 Days)
- VRCA 57.3K
- ZYXI 132.8K
- Earning Date
- VRCA 08-13-2025
- ZYXI 07-31-2025
- Dividend Yield
- VRCA N/A
- ZYXI N/A
- EPS Growth
- VRCA N/A
- ZYXI N/A
- EPS
- VRCA N/A
- ZYXI N/A
- Revenue
- VRCA $7,179,000.00
- ZYXI $172,401,000.00
- Revenue This Year
- VRCA $165.25
- ZYXI N/A
- Revenue Next Year
- VRCA $80.06
- ZYXI $19.55
- P/E Ratio
- VRCA N/A
- ZYXI N/A
- Revenue Growth
- VRCA N/A
- ZYXI N/A
- 52 Week Low
- VRCA $3.82
- ZYXI $1.66
- 52 Week High
- VRCA $71.40
- ZYXI $9.42
- Technical
- Relative Strength Index (RSI)
- VRCA 38.77
- ZYXI 53.86
- Support Level
- VRCA $5.86
- ZYXI $2.46
- Resistance Level
- VRCA $7.13
- ZYXI $2.82
- Average True Range (ATR)
- VRCA 0.88
- ZYXI 0.15
- MACD
- VRCA -0.28
- ZYXI 0.02
- Stochastic Oscillator
- VRCA 6.01
- ZYXI 57.14
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.